AJP - Heart Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 285: H1576-H1581, 2003. First published June 5, 2003; doi:10.1152/ajpheart.00217.2003
0363-6135/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
285/4/H1576    most recent
00217.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (23)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Russell, F. D.
Right arrow Articles by Molenaar, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russell, F. D.
Right arrow Articles by Molenaar, P.

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure

Fraser D. Russell,1 Deborah Meyers,2 Andrew J. Galbraith,2 Nick Bett,2 Istvan Toth,3 Philip Kearns,3 and Peter Molenaar1

Departments of 1Medicine and 2Cardiology, Prince Charles Hospital, Chermside, Queensland 4032; and 3School of Pharmacy, University of Queensland, St. Lucia, Queensland 4067, Australia

Submitted 10 March 2003 ; accepted in final form 3 June 2003

Human urotensin-II (hU-II) is the most potent endogenous cardiostimulant identified to date. We therefore determined whether hU-II has a possible pathological role by investigating its levels in patients with congestive heart failure (CHF). Blood samples were obtained from the aortic root, femoral artery, femoral vein, and pulmonary artery from CHF patients undergoing cardiac catheterization and the aortic root from patients undergoing investigative angiography for chest pain who were not in heart failure. Immunoreactive hU-II (hU-II-ir) levels were determined with radioimmunoassay. hU-II-ir was elevated in the aortic root of CHF patients (230.9 ± 68.7 pg/ml, n = 21; P < 0.001) vs. patients with nonfailing hearts (22.7 ± 6.1 pg/ml, n = 18). This increase was attributed to cardiopulmonary production of hU-II-ir because levels were lower in the pulmonary artery (38.2 ± 6.1 pg/ml, n = 21; P < 0.001) than in the aortic root. hU-II-ir was elevated in the aortic root of CHF patients with nonischemic cardiomyopathy (142.1 ± 51.5 pg/ml, n = 10; P < 0.05) vs. patients with nonfailing hearts without coronary artery disease (27.3 ± 12.4 pg/ml, n = 7) and CHF patients with ischemic cardiomyopathy (311.6 ± 120.4 pg/ml, n = 11; P < 0.001) vs. patients with nonfailing hearts and coronary artery disease (19.8 ± 6.6 pg/ml, n = 11). hU-II-ir was significantly higher in the aortic root than in the pulmonary artery and femoral vein, with a nonsignificant trend for higher levels in the aortic root than in the femoral artery. The findings indicated that hU-II-ir is elevated in the aortic root of CHF patients and that hU-II-ir is cleared at least in part from the microcirculation.

ischemic heart disease; dilated cardiomyopathy; circulating vasoactive agent


Address for reprint requests and other correspondence: F. D. Russell, Dept. of Medicine, Univ. of Queensland, Prince Charles Hospital, Rode Road, Chermside, Queensland 4032, Australia (E-mail: russell{at}medicine.uq.edu.au).




This article has been cited by other articles:


Home page
 Clin. Chem.Home page
Y.-H. Chen, T. G. Yandle, A. M. Richards, and S. C. Palmer
Urotensin II Immunoreactivity in the Human Circulation: Evidence for Widespread Tissue Release
Clin. Chem., November 1, 2009; 55(11): 2040 - 2048.
[Abstract] [Full Text] [PDF]

Home page
 Circ Heart FailHome page
M. P. Quaile, H. Kubo, C. L. Kimbrough, S. A. Douglas, and K. B. Margulies
Direct Inotropic Effects of Exogenous and Endogenous Urotensin-II: Divergent Actions in Failing and Nonfailing Human Myocardium
Circ Heart Fail, January 1, 2009; 2(1): 39 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
A. E. S. Abdel-Razik, R. J. Balment, and N. Ashton
Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II
Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1239 - F1247.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
T. Watanabe, K. Nishio, T. Kanome, T.-a. Matsuyama, S. Koba, T. Sakai, K. Sato, S. Hongo, K. Nose, H. Ota, et al.
Impact of Salusin-{alpha} and -{beta} on Human Macrophage Foam Cell Formation and Coronary Atherosclerosis
Circulation, February 5, 2008; 117(5): 638 - 648.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. Zoccali, F. Mallamaci, F. A. Benedetto, G. Tripepi, P. Pizzini, S. Cutrupi, and L. Malatino
Urotensin II and Cardiomyopathy in End-Stage Renal Disease
Hypertension, February 1, 2008; 51(2): 326 - 333.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Y.-X. Wang, Y.-J. Ding, Y.-Z. Zhu, Y. Shi, T. Yao, and Y.-C. Zhu
Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H348 - H359.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Lim, S. Honisett, C. D. Sparkes, P. Komesaroff, A. Kompa, and H. Krum
Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure
Circulation, March 16, 2004; 109(10): 1212 - 1214.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.